Skip to main content
. Author manuscript; available in PMC: 2019 Dec 1.
Published in final edited form as: Semin Arthritis Rheum. 2018 Mar 28;48(3):513–522. doi: 10.1016/j.semarthrit.2018.03.016

Table 3.

Factors associated with medications received by patients with juvenile dermatomyositis by logistic regression analysis.

IV Methylprednisolone
(N=182)		 Methotrexate (N=225) IV Immunoglobulin
(N=119)		 Antimalarial drugs (N=153) 2 or more major
medication combination
(N=242)
Univariabl
e analysis
OR (95%
CI)		 Multivariabl
e analysis
OR (95% CI)		 Univariabl
e analysis
OR (95%
CI)		 Multivaria
ble
analysis
OR (95%
CI)		 Univariable
analysis
OR (95% CI)		 Multivaria
ble
analysis
OR (95%
CI)		 Univariable
analysis
OR (95% CI)		 Multivariabl
e analysis
OR (95% CI)		 Univariabl
e analysis
OR (95%
CI)		 Multivaria
ble
analysis
OR (95%
CI)
Year of Diagnosis
 Before 1997 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
 After 1997 2.25 (1.37–3.76)† 2.38 (1.32–4.38)† 13.15 (5.65–38.41)§ 14.73 (5.62–50.93)§ 5.33 (3.23–8.96)§ 5.46 (3.05–10.00)§ 3.85 (2.34–6.47)§ 3.22 (1.79–5.94)‡ 9.44 (4.04–27.62)§ 10.75 (4.00–37.87)§
Age at first treatment 1.04 (0.98–1.10) 1.05 (0.99–1.13) 1.09 (1.02–1.16)† 1.09 (1.01–1.18)* 1.04 (0.99–1.10) 1.03 (0.96–1.10) 1.04 (0.98–1.10) 1.05 (0.98–1.13) 1.11 (1.04–1.20)† 1.13 (1.04–1.23)†
Gender
 Male 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
 Female 1.21 (0.75–1.95) 1.01 (0.60–1.70) 0.83 (0.51–1.36) 1.15 (0.71–1.86) 1.03 (0.58–1.78)
Race
 Caucasian 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
 Other Races 1.12 (0.69–1.82) 1.22 (0.72–2.11) 0.93 (0.57–1.53) 1.04 (0.64–1.67) 1.24 (0.71–2.23)
Onset Severity
 Moderate 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
 Mild 1.34 (0.66–2.78) 1.20 (0.53–2.75) 1.08 (0.51–2.41) 0.75 (0.29–1.97) 0.89 (0.40–1.88) 0.82 (0.32–2.02) 2.95 (1.40–6.56)† 2.93 (1.19–7.73)* 0.88 (0.41–1.98) 0.62 (0.24–1.65)
 Severe/Very Severe 3.37 (1.96–5.99)§ 3.00 (1.59–5.90)‡ 1.48 (0.85–2.66) 0.90 (0.45–1.83) 1.89 (1.13–3.14)* 1.72 (0.91–3.25) 1.21 (0.74–2.00) 1.15 (0.62–2.15) 2.33 (1.23–4.70)† 1.99 (0.92–4.57)
MSA
 All MSA negative 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
 Anti-p155/140 (TIF1) 2.54 (1.26–5.26)† 2.40 (1.10–5.35)* 2.77 (1.34–5.76)† 1.82 (0.80–4.16) 1.79 (0.85–3.94) 1.25 (0.53–3.04) 5.13 (2.44–11.40)§ 4.38 (1.93–10.51)‡ 2.44 (1.14–5.20)* 1.55 (0.65–3.64)
 Anti-MJ (NXP2) 2.36 (1.13–5.03)* 2.51 (1.14–5.69)* 2.40 (1.13–5.14)* 2.59 (1.13–6.03)* 1.88 (0.87–4.26) 1.64 (0.69–4.03) 1.71 (0.79–3.88) 1.96 (0.85–4.77) 1.86 (0.85–4.05) 1.97 (0.83–4.70)
 Anti-MDA5 2.54 (0.95–7.07) 2.44 (0.85–7.32) 1.46 (0.55–4.00) 0.92 (0.29–2.89) 1.67 (0.59–4.71) 1.29 (0.40–4.15) 2.67 (0.97–7.52) 2.57 (0.86–7.95) 1.71 (0.61–5.16) 1.04 (0.32–3.53)
Muscle symptom score 1.00 (0.99–1.02) 0.99 (0.98–1.01) 1.01 (1.00–1.02) 0.99 (0.98–1.01) 1.02 (1.01–1.03)‡ 1.01 (0.99–1.03) 1.00 (0.99–1.01) 1.00 (0.98–1.01) 1.01 (0.99–1.03) 0.99 (0.97–1.01)
Skin symptom score 1.02 (1.00–1.04)* 1.01 (0.99–1.03) 1.03 (1.01–1.05)† 1.03 (0.99–1.05) 1.03 (1.01–1.05)† 1.01 (0.99–1.04) 1.03 (1.01–1.05)‡ 1.01 (0.99–1.04) 1.04 (1.01–1.06)† 1.04 (1.01–1.07)†

Abbreviations: OR, Odds ratio; 95% CI, 95% Confidence interval; MSA, myositis autoantibodies; TIF1, transcription intermediary factor 1; NXP2, anti-nuclear matrix protein 2; Anti–MDA5, Anti–melanoma differentiation–associated gene 5. Age at first treatment and Symptoms scores were calculated by unit odds ratios (per unit change), and the range of variable were Age at first treatment; 1.3–18.8, Muscle symptoms score; 0–100, and Skin symptoms score; 0–61.

*

P <0.05,

†

P <0.01,

‡

P <0.001,

§

P <0.0001.